ActoBio Therapeutics

ActoBio Therapeutics is rated 3 out of 5 in the category biotechnology. Read and write reviews about ActoBio Therapeutics. ActoBio Therapeutics™ is pioneering a new class of healthcare agents, ActoBiotics®: microbial biopharmaceuticals that express and locally deliver disease-modifying therapeutics. ActoBiotics® are based on a safe food-grade microorganism, Lactococcus lactis, which is found in cheeses and other foods. The L. lactis are engineered to produce therapeutic biologics through oral or topical administration. ActoBiotics® have treatment applications across many diseases with the promise for safer and more efficacious treatments than injectable biologicals. 1995 Research on the Actobiotics® platform starts in the Flemish Institute for Biotechnology (VIB) and University of Ghent (UGent) Belgium 2006 ActoGeniX NV founded to commercialize and develop Actobiotics® 2015 Acquired by Intrexon Corporation (NYSE: XON) and renamed Intrexon ActoBiotics NV 2018 Doing business as ActoBio Therapeutics, a subsidiary of Intrexon Corporation. With significant progress on strain development and validation, expanding market opportunity in new disease areas, and several new partnerships ActoBio Therapeutics has a strong R&D pipeline with the latest stage candidate in Phase 2b and an extensive portfolio of candidates ready for clinical development across a number of potential indications. More about ActoBio Therapeutics: www.actobio.com More about Intrexon Corporation: www.dna.com For inquiries please contact: [email protected]